Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Multicenter, Parallel Group, Randomized Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Subjects With Unresectable or Metastatic Soft-tissue Sarcoma

NCT00718484 is registered in ClinicalTrials.gov with Alaunos Therapeutics as lead sponsor.

NCT NCT00718484
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00718484 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Multicenter, Parallel Group, Randomized Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Subjects With Unresectable or Metastatic Soft-tissue Sarcoma
Lead sponsor
Alaunos Therapeutics
Phase
Phase 2
Overall status
Terminated
Start date
September 3, 2008
Completion date
September 20, 2010
Enrollment
67 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

soft tissue sarcoma